LON:FARN Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis GBX 42 +0.50 (+1.20%) As of 12:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Faron Pharmaceuticals Oy Stock (LON:FARN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FARN alerts:Sign Up Key Stats Today's Range 39.60▼ 4250-Day Range 38.70▼ 58.3052-Week Range 38▼ 270Volume20,866 shsAverage Volume151,662 shsMarket Capitalization£83.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com Read More Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FARN Stock News HeadlinesFaron Pharmaceuticals Ltd: Termination of Liquidity Provision ServiceMay 6, 2026 | finance.yahoo.comFaron Pharmaceuticals Ends Liquidity Deal as Share Trading StrengthensMay 6, 2026 | tipranks.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 12 at 1:00 AM | Profits Run (Ad)Faron Pharmaceuticals Adds Veteran Biotech Dealmaker Golumbeski to BoardMay 5, 2026 | tipranks.comFaron AGM Backs Equity-Funding Flexibility and New Option Plan Amid Ongoing LossesMay 4, 2026 | tipranks.comFaron Resets Warrant Terms and Issues New Equity-Linked Instruments to IPFApril 30, 2026 | tipranks.comFaron partners with Parexel to run phase IIb trial of cancer immunotherapy bexmarilimab in blood disorder patientsApril 16, 2026 | uk.finance.yahoo.comFaron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDSApril 16, 2026 | finance.yahoo.comSee More Headlines FARN Stock Analysis - Frequently Asked Questions How have FARN shares performed this year? Faron Pharmaceuticals Oy's stock was trading at GBX 179 at the beginning of the year. Since then, FARN stock has decreased by 76.5% and is now trading at GBX 42. How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FARN CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (22.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£60.23 million Net MarginsN/A Pretax MarginN/A Return on Equity45.13% Return on Assets-70.00% Debt Debt-to-Equity Ratio-133.35 Current Ratio0.84 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2.10 per share Price / Cash Flow20.00 Book ValueGBX 1,957.36 per share Price / Book0.02Miscellaneous Outstanding Shares199,515,000Free FloatN/AMarket Cap£83.80 million OptionableNot Optionable Beta1.18 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:FARN) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersNNVC FDA = New Momentum Wave!NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targe...Equiscreen | SponsoredBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...Decentralized Masters | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredRise of the… petroyuan?On February 28th, Iran installed a yuan-denominated toll at the Strait of Hormuz - the chokepoint for one in e...Golden Portfolio | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FARN Stock Alerts